Overview
| Product name | Recombinant Human Interferon omega-1/IFNW1 Protein |
|---|
| Catalog No. | RP01752 |
|---|
| Description | Recombinant Human Interferon omega-1/IFNW1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly23-Ser195) of human Interferon omega-1/IFNW1 (Accession #NP_002168.1) fused with a 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured in a cell cytotoxicity assay using TF-1 cells. The ED50 for this effect is 0.13-0.54 ng/mL.
|
|---|
| Purity | > 97% by SDS-PAGE. |
|---|
| Endotoxin | < 0.1EU/μg |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
|---|
| Species | Human |
|---|
| Calculated MW | 20.88 kDa |
|---|
Background
IFNs are a large family of proteins having antiviral, antiproliferative, and immunomodulatory effects, and are divided into two major classes, type I and type II, based on differences in receptor binding and nucleotide sequence. Type I IFNs consist of IFN α, β, τ, and ω and bind to the type I IFN receptor, whereas IFN-γ is the only type II IFN and is specific for the type II IFN receptor. Human IFN-ω, was identified by three independent groups in 1985 and is structurally related to IFN-α and -β. Both human IFN-ω and IFN-α are produced by virally induced leukocytes and have similar antiviral activities on human cell lines, and a sizeable proportion (at least 1%) of the total antiviral activity of leukocyte IFN is contributed by IFN-ωl. Also, it was reported that IFN-ω could inhibit the growth of human tumors in vivo.
Product information
| Synonym | Interferon omega-1；IFNW1 |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-6His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
